CEO Philip Astley Sparke sold 17,902 stock shares in a deal dated May 16th. The shares were sold for an average of $18.05, resulting in a transaction totaling $323,131.10. After the completion of this transaction, the CEO now owns 1,525 278 shares of stock in the company, valued at about $27,531,267.90. This link will take you to a page that contains more information.
Replimune Group Trading Up 0.7 %
Trading on Thursday saw a $0.14 increase, bringing the price to $19.64. The stock traded 819,386 versus its average of 557,283 shares. The stock's market capitalization is $1.11 billion. It has a price to earnings ratio of -6.87, and a beta value of 1.65. The stock's 50-day simple moving is $18.00, and its 200-day simple moving is $21.84. Replimune Group, Inc.'s low for the past year was $13.47, and its high is $29.52. Many equity research analysts have published reports on the company. HC Wainwright raised their price target on Replimune Group to $50.00 from $48, and gave the company a buy' rating. This was in a report published on Friday, 10th February. Piper Sandler reiterated an 'overweight rating' and set a price target of $44.00 on shares in Replimune Group. This was published on Monday, April 17. Six analysts have given the stock a buy recommendation. According to MarketBeat data, Replimune Group's consensus rating is 'Buy,' with a price target of $51.67.
Institutional Investors Take a Stand on Replimune Group
REPL has recently been the subject of changes in REPL's holdings by institutional investors and hedge fund managers. TD Asset Management Inc. increased its Replimune Group stake by 26.6% during the fourth quarter. TD Asset Management Inc owns 132.963 shares worth $3.617,000, after buying an additional 27.962 shares. Emerald Advisers LLC grew its stake in Replimune Group from 4.4% to $4,617,000 in the fourth quarter. Emerald Advisers LLC owns 1,186.041 shares worth $32,260,000, after purchasing an additional 49.455 shares. Fisher Asset Management LLC purchased a new Replimune Group stake during the third quarter worth approximately $954,000. New York State Common Retirement Fund increased its stake in Replimune Group in the third quarter by 19.3%. New York State Common Retirement Fund owns 25,059 of the company’s stock worth $433,000, after purchasing 4,051 additional shares. Connor Clark & Lunn Investment Management Ltd. increased its stake in Replimune Group in the third quarter by 172.2%. Connor Clark & Lunn Investment Management Ltd. owns 29,170 of the company stock, valued at $504,000. This is after purchasing an additional 18,452 share during the period. Institutional investors own 87.83% the stock.
Replimune Group Company profile
Replimune Group, Inc. is a biotechnology company in clinical stages that develops oncolytic immunotherapy products candidates using the immulytic platform. Its product candidate include RP1, RP2, RP3. Oncolytic Immunotherapy, a cancer treatment offered by the firm, uses viruses that can selectively replicate and kill tumors. It also induces a powerful, patient-specific immune response against tumors.
MarketBeat.com offers a FREE daily email newsletter